Compare SFM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | PRAX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 9.6B |
| IPO Year | 2013 | 2020 |
| Metric | SFM | PRAX |
|---|---|---|
| Price | $75.87 | $320.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $112.92 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.9M | 364.5K |
| Earning Date | 05-25-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 5.31 | N/A |
| Revenue | ★ $8,806,159,000.00 | N/A |
| Revenue This Year | $9.03 | N/A |
| Revenue Next Year | $7.40 | $6,395.88 |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $64.75 | $26.70 |
| 52 Week High | $182.00 | $354.87 |
| Indicator | SFM | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 51.83 |
| Support Level | $64.88 | $290.36 |
| Resistance Level | $82.28 | N/A |
| Average True Range (ATR) | 3.48 | 17.96 |
| MACD | 1.22 | -2.78 |
| Stochastic Oscillator | 77.62 | 51.76 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.